Reports related to this article:
Project(s): View 1 related project in PECWeb
Released May 22, 2023 | GALWAY, IRELAND
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--U.S. medical device company Dexcom Incorporated (NYSE:DXCM) (San Diego) has chosen Ireland for its first European manufacturing site.
The company, which specializes in continuous glucose monitoring (CGM) for people with diabetes, is planning to spend up to 300 million euro (US$326 million) over the next five years to construct a new manufacturing facility in Athenry, Galway, in the west of the country. The project has the support of the Irish Government through the IDA Ireland agency and has the potential to create up to 1,000 high skilled jobs over the same period. Subject to planning permission, the new facility will have the capacity to produce millions of Dexcom CGM sensors each year. The products are used by diabetes sufferers to track glucose levels continuously throughout the day and night, with real-time alerts sent to smart devices. Late last year, Ireland was an initial launch market globally for the Dexcom G7, the company's latest CGM all-in-one wearable.
"With the continued success of our Dexcom G7 in Europe, we are pursuing an ambitious growth strategy that requires increased manufacturing capacity to support our rapidly expanding European user base," said Barry Regan, executive vice president of Global Operations at Dexcom. "Ireland has an exceptional talent pool and an established MedTech sector, making Athenry the perfect location for us to establish a new, state-of-the-art manufacturing facility."
The move was welcomed by Ireland's Taoiseach Leo Varadkar: "Congratulations to all at Dexcom on this move, which is great news for local employment and the local economy in Galway and the wider region, both during the initial construction phase, and even more so thereafter with the creation of up to 1,000 high tech graduate and technician positions expected in the coming years. I was pleased to meet with Dexcom this time last year when I visited their headquarters in San Diego. This will be one of the biggest single private sector investments ever in the West of Ireland. In addition to the thousand jobs being created by the company, it will bring many spin-off opportunities, jobs and contracts for other businesses in the region. The announcement that Athenry is to become Dexcom's first manufacturing site in Europe is very much in line with the Government's policy of balanced regional development. It has been enabled by major government investment in infrastructure in the area and a lot of hard work on the part of IDA Ireland."
The facility in Athenry will contain a "highly automated and efficient manufacturing operation with an emphasis on green technologies," the company stated. There is no information yet on construction timeline nor commissioning. It will be located at an 89-hectare landbank site owned by the IDA that is zoned for "utility intensive type investment such as major biotech together with office and research-based activities." Dexcom has global manufacturing facilities in Mesa, Arizona and Batu Kawan, Malaysia.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
The company, which specializes in continuous glucose monitoring (CGM) for people with diabetes, is planning to spend up to 300 million euro (US$326 million) over the next five years to construct a new manufacturing facility in Athenry, Galway, in the west of the country. The project has the support of the Irish Government through the IDA Ireland agency and has the potential to create up to 1,000 high skilled jobs over the same period. Subject to planning permission, the new facility will have the capacity to produce millions of Dexcom CGM sensors each year. The products are used by diabetes sufferers to track glucose levels continuously throughout the day and night, with real-time alerts sent to smart devices. Late last year, Ireland was an initial launch market globally for the Dexcom G7, the company's latest CGM all-in-one wearable.
"With the continued success of our Dexcom G7 in Europe, we are pursuing an ambitious growth strategy that requires increased manufacturing capacity to support our rapidly expanding European user base," said Barry Regan, executive vice president of Global Operations at Dexcom. "Ireland has an exceptional talent pool and an established MedTech sector, making Athenry the perfect location for us to establish a new, state-of-the-art manufacturing facility."
The move was welcomed by Ireland's Taoiseach Leo Varadkar: "Congratulations to all at Dexcom on this move, which is great news for local employment and the local economy in Galway and the wider region, both during the initial construction phase, and even more so thereafter with the creation of up to 1,000 high tech graduate and technician positions expected in the coming years. I was pleased to meet with Dexcom this time last year when I visited their headquarters in San Diego. This will be one of the biggest single private sector investments ever in the West of Ireland. In addition to the thousand jobs being created by the company, it will bring many spin-off opportunities, jobs and contracts for other businesses in the region. The announcement that Athenry is to become Dexcom's first manufacturing site in Europe is very much in line with the Government's policy of balanced regional development. It has been enabled by major government investment in infrastructure in the area and a lot of hard work on the part of IDA Ireland."
The facility in Athenry will contain a "highly automated and efficient manufacturing operation with an emphasis on green technologies," the company stated. There is no information yet on construction timeline nor commissioning. It will be located at an 89-hectare landbank site owned by the IDA that is zoned for "utility intensive type investment such as major biotech together with office and research-based activities." Dexcom has global manufacturing facilities in Mesa, Arizona and Batu Kawan, Malaysia.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
